Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses
Journal of Gynecologic Oncology · 2026 · 37 (3)
DOI: 10.3802/jgo.2026.37.e65 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Gynecologic Oncology, 2026. Verfasst von Jung-Yun Lee und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.…. Hauptthemen laut MEDLINE: Erb-b2 Receptor Tyrosine Kinases, Genital Neoplasms, Female, Trastuzumab, Camptothecin. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, AstraZeneca.
Abstract (Originalsprache)
OBJECTIVE: To investigate antitumor activity, safety, and exploratory subgroup analyses for trastuzumab deruxtecan (T-DXd) in human epidermal growth factor receptor 2 (HER2)-expressing (immunohistochemistry [IHC] 3+ and 2+) gynecologic cancers. METHODS: DESTINY-PanTumor02 is a 2-part, open-label, multicenter, phase 2 study. Pretreated patients with locally advanced, metastatic, or unresectable HER2-expressing solid tumors received T-DXd 5.4 mg/kg. Primary endpoint was investigator-assessed (INV) confirmed objective response rate (ORR). Secondary endpoints included safety, ORR by independent central review (ICR), progression-free survival, and overall survival. Exploratory endpoints included ORRs by biomarker status. This analysis reports data from the endometrial, cervical, and ovarian cancer cohorts. RESULTS: At primary analysis data cutoff, 120 patients received treatment across 3 gynecologic cancer cohorts. Median follow-up (range) was 19.9 months (0.8-31.1), 12.6 months (0.9-31.0), and 13.1 months (0.7-30.6) in the endometrial, cervical, and ovarian cancer cohorts, respectively. INV confirmed ORRs (n/N [95% confidence interval]) in the endometrial, cervical, and ovarian cancer cohorts were 57.5% (23/40 [40.9-73.0]), 50.0% (20/40 [33.8-66.2]), and 45.0% (18/40 [29.3-61.5]), respectively, and by ICR were 57.5% (23/40 [40.9-73.0]), 37.5% (15/40 [22.7-54.2]), and 42.5% (17/40 [27.0-59.1]), respectively. ORRs were highest for the HER2 IHC 3+ populations. Although patient numbers were small in some subgroups, objective responses were observed regardless of tumor histology, prior treatment, and biomarker expression/mutation status. Adjudicated interstitial lung disease/pneumonitis occurred in 13 patients (10.8%; Grade 1, n=4; Grade 2, n=8; Grade 5, n=1). CONCLUSION: T-DXd induced clinically meaningful ORRs, with safety consistent with the known profile. Data further support T-DXd as a therapeutic option for pretreated HER2-expressing gynecologic cancers. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04482309.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. jungyunlee@yuhs.ac.
- Medical Oncology Service, Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
- Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
- Medical Oncology Department and Programme in Solid Tumours CIMA, Cancer Center Clínica Universidad de Navarra, Madrid, Spain.
- Center for Excellence in Precision Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
ORCID-Profile: Jung-Yun Lee, Ana Oaknin, Luis Manso, Antonio González-Martín, Iwona Ługowska, Domenica Lorusso, Susana Banerjee, John B Liao, Chien-Hsing Lu, Naiyarat Prasongsook, Bohuslav Melichar, Chiedozie Anoka, Lindsey Jung, Flavia Michelini, Soham Puvvada, Funda Meric-Bernstam, Vicky Makker
Förderung
- NCI NIH HHS
- AstraZeneca
Zitieren
APA
Lee, J. Y., Oaknin, A., Manso, L., González-Martín, A., Ługowska, I., Lorusso, D., Banerjee, S., Liao, J. B., Lu, C. H., Prasongsook, N., Melichar, B., Anoka, C., Jung, L., Michelini, F., Puvvada, S., Meric-Bernstam, F., & Makker, V. (2026). Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. Journal of Gynecologic Oncology, 37(3). https://doi.org/10.3802/jgo.2026.37.e65
Vancouver
Lee JY, Oaknin A, Manso L, González-Martín A, Ługowska I, Lorusso D, et al. Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses. Journal of Gynecologic Oncology. 2026;37(3). doi:10.3802/jgo.2026.37.e65
BibTeX
@article{Lee2026,
author = {Lee, Jung-Yun and Oaknin, Ana and Manso, Luis and González-Martín, Antonio and Ługowska, Iwona and Lorusso, Domenica and Banerjee, Susana and Liao, John B and Lu, Chien-Hsing and Prasongsook, Naiyarat and Melichar, Bohuslav and Anoka, Chiedozie and Jung, Lindsey and Michelini, Flavia and Puvvada, Soham and Meric-Bernstam, Funda and Makker, Vicky},
title = {Trastuzumab deruxtecan in HER2-expressing gynecologic cancers from DESTINY-PanTumor02: antitumor activity, safety, and exploratory biomarker analyses},
journal = {Journal of Gynecologic Oncology},
year = {2026},
volume = {37},
number = {3},
doi = {10.3802/jgo.2026.37.e65}
}
EUVIMED